CTIS2024-511684-28-00进行中（未招募）1 期
ong-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors. - AUTO-LT1
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 111
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Patients must have received an AUTO CAR T cell therapy on a previous treatment study., Patients must have provided informed consent for long-term follow-up study prior to participation., Patients must be able to comply with the study requirements.
排除标准
- •There are no exclusion criteria for this study.
研究者
相似试验
进行中（未招募）
1 期
ong-term follow-up of patients previously treated with an Autolus CAR T cell therapyEUCTR2016-004867-38-NLAutolus Limited500
进行中（未招募）
1 期
ong-term follow-up of patients previously treated with an Autolus CAR T cell therapyEUCTR2016-004867-38-GBAutolus Limited500
撤回
2 期
ong-term follow-up of patients previously treated with autologous T cells genetically modified with retroviral vectors.Plasma Cell Neoplasm, Lymphomas non-Hodgkin's B-cell, Lymphomas non-Hodgkin's T-cell and Leukaemias10024324CancerNL-OMON46028Autolus Limited32
进行中（未招募）
1 期
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864EUCTR2016-000297-38-BEInstitut de Recherches Internationales Servier (I.R.I.S)200
进行中（未招募）
1 期
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864EUCTR2016-000297-38-FRInstitut de Recherches Internationales Servier (I.R.I.S)200